U.S. markets closed

Myovant Sciences Ltd. (MYOV)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
22.18+0.35 (+1.60%)
At close: 4:00PM EDT
23.65 +1.47 (6.63%)
After hours: 06:17PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Performance Outlook
Previous Close21.83
Open21.70
Bid22.31 x 1200
Ask22.55 x 800
Day's Range21.24 - 22.22
52 Week Range13.42 - 30.90
Volume579,681
Avg. Volume713,243
Market Cap2.042B
Beta (5Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-3.13
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Myovant Sciences Ltd.
    CARA: Lowering target price to $12.00CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Benzinga

    3 Stocks Insiders Are Buying

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Asana The Trade: Asana,

  • Zacks

    Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA

    Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.

  • GlobeNewswire

    Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

    Filing in endometriosis is supported by data from the Phase 3 SPIRIT programFDA PDUFA target action date is May 6, 2022 BASEL, Switzerland and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pa